News & Updates
Filter by Specialty:

Novel SERD shows promise for ER+/HER2– advanced/metastatic breast cancer
The novel oral SERD* elacestrant demonstrated potential as new treatment alternative for ER+/HER2– advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy, according to the phase III EMERALD trial.
Novel SERD shows promise for ER+/HER2– advanced/metastatic breast cancer
30 Dec 2021
Early mortality high among multiple myeloma patients
Though decreasing over time, early mortality remains high in patients with multiple myeloma (MM), a recent study has found. Important risk factors include older age, a more aggressive disease, and a patient’s poor physical condition.
Early mortality high among multiple myeloma patients
30 Dec 2021
Post-diagnosis use of risk stratification tools improves assessment of SMM patients
Despite only being validated for use at diagnosis, risk stratification scores, such as the Mayo-2018 and the International Myeloma Working Group (IMWG)-2020 criteria, appear to be viable for post-diagnosis use in patients with smouldering multiple myeloma (SMM), a recent study has found.